Pudong New Area Highlights Tee Labs: Supporting Scientific Innovation from 0 to 1, Nurturing Biotech Startups
October 11, 2023 Pudong New Area published an article titled "Supporting Scientific Innovation from 0 to 1: Tee Labs Nurtures Biotech Startups", recognizing Tee Labs’ contributions to advancing domestic pharmaceutical innovation.
Since its establishment, Tee Labs has provided comprehensive support to biotech startups—including R&D facilities, corporate functions, integrated supply chain services, and funding.
Within Tee Labs’ 2,600 m² incubation space, 1,500 m² is dedicated to specialized laboratories for chemistry, molecular biology, cell culture, bacterial culture, and BSL-2 . As incubated teams optimize their workflows, Tee Labs not only maintains facilities and laboratory equipment but also co-incubates projects. Committed to being a true entrepreneurial partner, Tee Labs collaborates with—and even guides—founders in validating scientific concepts, assessing commercial potential, clinical applications, and development pathways. At Tee Labs, scientists and entrepreneurs foster an environment of open exchange, collaboration, and knowledge-sharing.
Dr. Ni Lin, Founder of Tee Labs, integrates her multidisciplinary expertise—spanning drug R&D, pharmaceutical executive leadership, and investment—into the incubator platform. This maximizes empowerment for startups, accelerating their R&D velocity. With a decade of venture capital experience, Dr. Ni has repeatedly guided biotech companies from inception (“0 to 1”). She emphasizes that professional biotech incubation demands deep, long-term industry insight: “Innovation in biopharma is a marathon. Time, experience, and resources must accumulate meaningfully. China no longer lacks infrastructure; what it needs are innovators who profoundly understand the industry, effectively integrate resources, strategize projects, and execute them to fruition.”
Tee Labs will enhance its incubation capabilities through three key initiatives:
- Accelerate resource integration across research, industry, and clinical realms to build a “clinical-academic-industrial” ecosystem, delivering precise strategic guidance for incubated companies.
- Deepen collaborations with multinational pharma to expand opportunities for co-development, overseas expansion, and M&A.
- Diversify funding channels by connecting incubated projects with private capital to accelerate commercialization.
We invite entrepreneurs committed to novel drug development to join us in advancing human health and accelerating China’s scientific innovation journey.